Safety, Efficacy and MRD Negativity of a Combination of Venetoclax and Obinutuzumab in Patients with Previously Untreated Chronic Lymphocytic Leukemia - Results from a Phase 1b Study (GP28331)

被引：0
|
作者：
Flinn, Ian W.
Gribben, John G.
Dyer, Martin J. S.
Wierda, William G.
Maris, Michael B.
Furman, Richard R.
Hillmen, Peter
Jones, Jeffrey
Iyer, Swami P.
Jones, Surai
Jiang, Yanwen
Pignataro, Daniela Soriano
Humphrey, Kathryn
Mobasher, Mehrdad
Kipps, Thomas J.
机构：
来源：
BLOOD | 2017年 / 130卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
430
引用
收藏
页数：4
相关论文
共 50 条
  • [21] Venetoclax-Obinutuzumab for Previously Untreated Chronic Lymphocytic Leukemia: 5-Year Results of the Randomized CLL14 Study
    Al-Sawaf, Othman
    Zhang, Can
    Robrecht, Sandra
    Kotak, Alex
    Chang, Naomi
    Fink, Anna
    Tausch, Eugen
    Schneider, Christof
    Ritgen, Matthias
    Kreuzer, Karl
    Chyla, Brenda
    Eichhorst, Barbara
    Jiang, Yanwen
    Stilgenbauer, Stephan
    Hallek, Michael
    Fischer, Kirsten
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S274 - S275
  • [22] Venetoclax-obinutuzumab for previously untreated chronic lymphocytic leukemia: 6-year results of the randomized CLL14 study
    Al-Sawaf, Othman
    Robrecht, Sandra
    Zhang, Can
    Olivieri, Stefano
    Chang, Naomi
    Fink, Anna
    Tausch, Eugen
    Ritgen, Matthias
    Kreuzer, Karl
    Sivcheva, Lilly
    Niemann, Carsten
    Schwarer, Anthony
    Loscertales, Javier
    Weinkove, Robert
    Strumberg, Dirk
    Kilfoyle, Allanah
    Runkel, Eva
    Eichhorst, Barbara
    Stilgenbauer, Stephan
    Jiang, Yanwen
    Hallek, Michael
    Fischer, Kirsten
    LEUKEMIA & LYMPHOMA, 2023, 64 : S113 - S113
  • [23] Updated Safety and Preliminary Efficacy Data from a Phase 1b Study Combining Venetoclax (GDC-0199, ABT-199) with Bendamustine/Rituximab in Patients with Relapsed/Refractory or Previously Untreated Chronic Lymphocytic Leukemia
    Salles, Gilles A.
    Boyd, Thomas E.
    Morschhauser, Franck
    Wendtner, Clemens-Martin
    Hallek, Michael
    Eichhorst, Barbara F.
    Kozloff, Mark
    Cartron, Guillaume
    Li, Yan
    Hilger, James
    Mobasher, Mehrdad
    Stilgenbauer, Stephan
    BLOOD, 2015, 126 (23)
  • [24] Phase 2, multicenter GIBB study of obinutuzumab plus bendamustine in previously untreated patients with chronic lymphocytic leukemia
    Sharman, Jeff P.
    Burke, John M.
    Yimer, Habte A.
    Boxer, Michael A.
    Babu, Sunil
    Li, Jia
    Mun, Yong
    Danilov, Alexey V.
    LEUKEMIA & LYMPHOMA, 2021, 62 (04) : 791 - 800
  • [25] Phase Ib Study (GO28440) of Venetoclax with Bendamustine/Rituximab or Bendamustine/Obinutuzumab in Patients with Relapsed/ Refractory or Previously Untreated Chronic Lymphocytic Leukemia
    Stilgenbauer, Stephan
    Morschhauser, Franck
    Wendtner, Clemens-Martin
    Cartron, Guillaume
    Hallek, Michael
    Eichhorst, Barbara F.
    Kozloff, Mark
    Giever, Thomas A.
    Lozanski, Gerard
    Punnoose, Elizabeth A.
    Wang, Jue
    Hilger, James
    Mobasher, Mehrdad
    Salles, Gilles
    BLOOD, 2016, 128 (22)
  • [26] Phase 1b Results of a Phase 1b/2 Study of Obinutuzmab, Ibrutinib, and Venetoclax in Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)
    Jones, Jeffrey A.
    Woyach, Jennifer
    Awan, Farrukh T.
    Maddocks, Kami J.
    Whitlow, Thomas
    Ruppert, Amy S.
    Byrd, John C.
    BLOOD, 2016, 128 (22)
  • [27] Results of a phase II multicenter study of obinutuzumab plus bendamustine in pts with previously untreated chronic lymphocytic leukemia (CLL).
    Sharman, Jeff Porter
    Yimer, Habte Aragaw
    Boxer, Michael
    DiBella, Nicholas
    Babu, Sunil
    Li, Jia
    Mun, . . . Yong Jun
    Skettino, Sandra L.
    Danilov, Alexey Valeryevich
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [28] Improvements in Health-Related Quality of Life and Symptoms in Patients with Previously Untreated Chronic Lymphocytic Leukemia: Results from the Phase II GIBB Study of the Combination of Obinutuzumab and Bendamustine
    Sharman, Jeffrey P.
    Yimer, Habte
    Boxer, Michael
    Di Bella, Nicholas
    Babu, Sunil
    Li, Jia
    Mun, Yong
    Trask, Peter
    Masaquel, Anthony
    Reyes, Carolina M.
    Danilov, Alexey
    BLOOD, 2017, 130
  • [29] Preliminary Safety Results from the Phase IIIb GREEN Study of Obinutuzumab (GA101) Alone or in Combination with Chemotherapy for Previously Untreated or Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)
    Bosch, Francesc
    Illmer, Thomas
    Turgut, Mehmet
    Cortelezzi, Agostino
    Lasserre, Susan F.
    Truppel-Hartmann, Anna
    Leblond, Veronique
    Foa, Robin
    Stilgenbauer, Stephan
    BLOOD, 2014, 124 (21)
  • [30] Obinutuzumab Alone or Combined with Chemotherapy in Previously Untreated (Fit or Unfit) or Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) Patients: Final Results from the Phase IIIb GREEN Safety Study with a Focus on Efficacy
    Stilgenbauer, Stephan
    Bosch, Francesc
    Leblond, Veronique
    Ilhan, Osman
    Kisro, Jens
    Mahe, Beatrice
    Mikuskova, Eva
    Osmanov, Dzhelil
    Reda, Gianluigi
    Tausch, Eugen
    Wojtowicz, Marcin
    Perretti, Thomas
    Van Hoef, Marlies E. H. M.
    Foa, Robin
    BLOOD, 2019, 134
12345